These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 22993308)
1. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours. Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308 [TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Niederle MB; Hackl M; Kaserer K; Niederle B Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725 [TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998 [TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737 [TBL] [Abstract][Full Text] [Related]
5. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
6. Cocaine- and amphetamine-regulated transcript in neuroendocrine tumors. Landerholm K; Falkmer SE; Järhult J; Sundler F; Wierup N Neuroendocrinology; 2011; 94(3):228-36. PubMed ID: 21832817 [TBL] [Abstract][Full Text] [Related]
7. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240 [TBL] [Abstract][Full Text] [Related]
8. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Klöppel G Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112 [TBL] [Abstract][Full Text] [Related]
9. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related]
10. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731 [TBL] [Abstract][Full Text] [Related]
11. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537 [TBL] [Abstract][Full Text] [Related]
13. Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases. Stoica-Mustafa E; Pechianu C; Iorgescu A; Hortopan M; Dima SO; Tomulescu V; Dumitraşcu T; Ungureanu C; Andronesi D; Popescu I; Herlea V Rom J Morphol Embryol; 2012; 53(2):351-5. PubMed ID: 22732805 [TBL] [Abstract][Full Text] [Related]
14. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Briest F; Grabowski P Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868 [TBL] [Abstract][Full Text] [Related]
15. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases. Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631 [TBL] [Abstract][Full Text] [Related]
17. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Berković MC; Jokić M; Marout J; Radosević S; Zjacić-Rotkvić V; Kapitanović S Exp Mol Pathol; 2007 Dec; 83(3):474-9. PubMed ID: 17950274 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Lindholm DP; Oberg K Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449 [TBL] [Abstract][Full Text] [Related]
19. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111 [TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]